The study aims to study the demographic trends in the mortality rates of Myasthenia Gravis in the United States from 1999 to 2020.

Myasthenia gravis affects an estimated 36,000 to 60,000 people in the US, with a prevalence of approximately 14 to 20 cases per 100,000 people. The incidence and prevalence of this condition have doubled over the past two decades.

We utilized the mortality data from 1999 to 2020 from the CDC WONDER database for Myasthenia Gravis as a cause of death, using ICD-10 code G70.0. The age-adjusted mortality rates (AAMR)/1,000,000 of the population were extracted, and trends were analyzed for gender, race, year, census region, and state. Joinpoint regression was used to calculate the AAMR annual percent change (APC) with 95% CI for race and gender.

Between 1999 and 2020, Myasthenia Gravis accounted for 31,392 deaths in the US. The AAMR increased from 4 in 1999 to 6.1 in 2020, with a consistent upward trend observed after 2009. The APC increased by 2.09 from 2009 to 2018, followed by a decrease of -2.0 till 2019 and sudden spike of 20.73 till 2020.Males consistently exhibited higher AAMR than females (1999 Male AAMR: 5.3 vs. Female AAMR: 3.3, 2020 Male AAMR: 8.6 vs. Female AAMR: 4.3). Non-Hispanic (NH) Whites recorded the highest AAMR (4.8), trailed by Hispanics or Latinos (2.8), and NH Blacks (2.4). Vermont registered the highest state-level AAMR at 5.8 while Alaska and the District of Columbia reported the lowest at 2.9 and 2.5, respectively.

Our analysis of CDC WONDER data from 1999 to 2020 indicates an observed increase in mortality rates related to Myasthenia Gravis in the United States. Males consistently exhibited higher rates than females, with notable racial disparities. These findings emphasize the importance of implementing targeted interventions to address the evolving burden of MG mortality.